← Leaderboards
Richard Goff James
University Of Washington
$5,481,094
Attributed
$7,856,727
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,856,727 · 5
By mechanism
R01$6,885,260 · 3
R00$717,235 · 1
K99$254,232 · 1
Top collaborators
- Adrian M Piliponsky9 shared
Most similar at University Of Washington
Same institution · by research overlap
- Hans D Ochs$9,229,500
- Robert E Braun$36,663,443
- Alexander Richard Paredez$5,038,624
- Leo J Pallanck$10,408,744
- Theresa A Jones$219,953
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingCellsSignal TransductionBaseMolecularResponseProteinsIn VivoReportingPlayProteomicsImpairmentImmuneReporterMass Spectrum AnalysisReconstitutionDiagnosisMutationCell LinePathway InteractionsMonitorInvestigationAmino AcidsPhosphorylation
Grant awards (19)
Critical role for Solute Carrier Proteins (SLCs) for mast cell function$1,058,168
R01 · FY2025 · AI
Critical role for Solute Carrier Proteins (SLCs) for mast cell function$734,048
R01 · FY2024 · AI
Critical role for Solute Carrier Proteins (SLCs) for mast cell function$750,025
R01 · FY2023 · AI
Critical role for Solute Carrier Proteins (SLCs) for mast cell function$521,208
R01 · FY2022 · AI
Role of Dock8 in Mucosal Immunity$288,272
R01 · FY2022 · AI · contact PI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma$423,680
R01 · FY2021 · CA · contact PI
Role of Dock8 in Mucosal Immunity$288,600
R01 · FY2021 · AI · contact PI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma$423,667
R01 · FY2020 · CA · contact PI
Role of Dock8 in Mucosal Immunity$288,600
R01 · FY2020 · AI · contact PI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma$411,320
R01 · FY2019 · CA · contact PI
Role of Dock8 in Mucosal Immunity$274,115
R01 · FY2019 · AI · contact PI
Role of Dock8 in Mucosal Immunity$548,230
R01 · FY2018 · AI · contact PI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma$427,373
R01 · FY2018 · CA · contact PI
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphoma$447,954
R01 · FY2017 · CA · contact PI
In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop$235,353
R00 · FY2014 · HL · contact PI
In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop$232,883
R00 · FY2013 · HL · contact PI
In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop$248,999
R00 · FY2012 · HL · contact PI
In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop$127,116
K99 · FY2011 · HL · contact PI
In vivo role of BTK-mediated inhibition of Wnt/b-catenin signaling during hematop$127,116
K99 · FY2010 · HL · contact PI